Top

Published in:

01-07-2013 | Original Article

Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas

Authors: Cláudia Malheiros Coutinho-Camillo, Silvia Vanessa Lourenço, Suely Nonogaki, José Guilherme Vartanian, Maria Aparecida Nagai, Luiz Paulo Kowalski, Fernando Augusto Soares

Published in: Virchows Archiv | Issue 1/2013

Abstract

PAR-4 is a tumor suppressor protein with a pro-apoptotic function and down-regulation of PAR-4 is seen in a variety of tumors. PHLDA1 gene overexpression has been shown to reduce cell proliferation and induce cell death in a variety of cell types. In this study, 229 cases of oral squamous cell carcinoma (OSCC), arranged in a tissue microarray, were analyzed by immunohistochemistry. PAR-4 expression was predominantly moderate to strong and expression of PHLDA1 was predominantly negative or weak. Cytoplasmic expression of PAR-4 was associated with advanced clinical stage. Expression of PHLDA1 was associated with advanced clinical stage of the tumour. Five-year overall and disease-free survival rates differed significantly between cases that did and cases that did not express PHLDA1, and by multivariate analysis, expression of PHLDA1 and PAR-4 were independent prognostic factors in OSCC patients. Expression of PAR-4 and PHLDA1 is altered in OSCC and might be a valuable prognostic indicator for this disease.

Massano J, Regateiro FS, Januário G, Ferreira A (2006) Oral Squamous cell carcinoma: review of prognostic and predictive factors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:67–76PubMedCrossRef

Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 (2012) CA Cancer J Clin 62(1):10–29

da Saúde M (2011) Ministério da Saúde. Instituto Nacional do Câncer. Estimativa/2012. Incidência de Câncer no Brasil. Rio de. Janeiro, INCA

Schoelch ML, Le QT, Silverman S Jr, McMillan A, Dekker NP, Fu KK, Ziober BL, Regezi JA (1999) Apoptosis-associated proteins and the development of oral squamous cell carcinoma. Oral Oncol 35(1):77–85PubMedCrossRef

Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, Kowalski LP, Soares FA (2010) Expression of Bcl-2 family proteins and association with clinicopathological characteristics of oral squamous cell carcinoma. Histopathology 57(2):304–316PubMedCrossRef

Coutinho-Camillo CM, Lourenço SV, Nishimoto IN, Kowalski LP, Soares FA (2011) Caspase expression in oral squamous cell carcinoma. Head Neck 33(8):1191–1198PubMedCrossRef

Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674PubMedCrossRef

Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70PubMedCrossRef

Zhao Y, Rangnekar VM (2008) Apoptosis and tumor resistance conferred by Par-4. Cancer Biol Ther 7:1867–1874PubMedCrossRef

10.

Cook J, Krishnan S, Ananth S, Sells SF, Shi Y, Walther MM, Linehan WM, Sukhatme VP, Weinstein MH, Rangnekar VM (1999) Decreased expression of the pro-apoptotic protein Par-4 in renal cell carcinoma. Oncogene 18:1205–1208PubMedCrossRef

11.

Kogel D, Reimertz C, Mech P, Poppe M, Fruhwald MC, Engemann H, Scheidtmann KH, Prehn JH (2001) Dlk/ZIP kinase-induced apoptosis in human medulloblastoma cells: requirement of the mitochondrial apoptosis pathway. Br J Cancer 85:1801–1808PubMedCrossRef

12.

Boehrer S, Chow KU, Puccetti E, Ruthardt M, Godzisard S, Krapohl A, Schneider B, Hoelzer D, Mitrou PS, Rangnekar VM, Weidmann E lymphocytes and inverse expressional patterns of par-4 and bcl-2 in acute lymphocytic leukemia. Hematol J 2:103–107

13.

Nagai MA, Gerhard R, Salaorni S, Fregnani JH, Nonogaki S, Netto MM, Soares FA (2010) Down-regulation of the candidate tumor suppressor gene PAR-4 is associated with poor prognosis in breast cancer. Int J Oncol 37(1):41–49PubMedCrossRef

14.

Moreno-Bueno G, Fernandez-Marcos PJ, Collado M, Tendero MJ, Rodriguez-Pinilla SM, Garcia-Cao I, Hardisson D, Diaz-Meco MT, Moscat J, Serrano M, Palacios J (2007) Inactivation of the candidate tumor suppressor par-4 in endometrial cancer. Cancer Res 67:1927–1934PubMedCrossRef

15.

Lee JW, Hsiao WT, Lee KF, Sheu LF, Hsu HY, Hsu SB, Lee MS, Hsu YC, Chang CH (2010) Widespread expression of prostate apoptosis response-4 in nasopharyngeal carcinoma. Head Neck 32(7):877–885PubMed

16.

Frank D, Mendelsohn CL, Ciccone E, Svensson K, Ohlsson R, Tycko B (1999) A novel pleckstrin homology-related gene family defined by Ipl/Tssc3, TDAG51, and Tih1: tissue-specific expression, chromosomal location, and parental imprinting. Mamm Genome 10(12):1150–1159PubMedCrossRef

17.

Park CG, Lee SY, Kandala G, Lee SY, Choi Y (1996) A novel gene product that couples TCR signaling to Fas(CD95) expression in activation-induced cell death. Immunity 4(6):583–591PubMedCrossRef

18.

Gomes I, Xiong W, Miki T, Rosner MR (1999) A proline- and glutamine-rich protein promotes apoptosis in neuronal cells. J Neurochem 73(2):612–622PubMedCrossRef

19.

Hossain GS, van Thienen JV, Werstuck GH, Zhou J, Sood SK, Dickhout JG, de Koning AB, Tang D, Wu D, Falk E, Poddar R, Jacobsen DW, Zhang K, Kaufman RJ, Austin RC (2003) TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278(32):30317–30327PubMedCrossRef

20.

Neef R, Kuske MA, Pröls E, Johnson JP (2002) Identification of the human PHLDA1/TDAG51 gene: down-regulation in metastatic melanoma contributes to apoptosis resistance and growth deregulation. Cancer Res 62:5920–5929PubMed

21.

Nagai MA, Fregnani JHTG, Netto MM, Brentani MM, Soares FA (2007) Down-regulation of PHLDA1 gene expression is associated with breast cancer progression. Breast Cancer Res Treat 106:49–56PubMedCrossRef

22.

Shrestha-Bhattarai T, Rangnekar VM (2010) Cancer-selective apoptotic effects of extracellular and intracellular Par-4. Oncogene 29(27):3873–3880PubMedCrossRef

23.

Goswami A, Ranganathan P, Rangnekar VM (2006) The phosphoinositide 3-kinase/Akt1/Par-4 axis: a cancer-selective therapeutic target. Cancer Res 66(6):2889–2892PubMedCrossRef

24.

Qiu G, Ahmed M, Sells SF, Mohiuddin M, Weinstein MH, Rangnekar VM (1999) Mutually exclusive expression patterns of Bcl-2 and Par-4 in human prostate tumors consistent with down-regulation of Bcl-2 by Par-4. Oncogene 18(3):623–631PubMedCrossRef

25.

Burikhanov R, Zhao Y, Goswami A, Qiu S, Schwarze SR, Rangnekar VM (2009) The tumor suppressor Par-4 activates an extrinsic pathway for apoptosis. Cell 138(2):377–388PubMedCrossRef

26.

Sharma AK, Kline CL, Berg A, Amin S, Irby RB (2011) The Akt Inhibitor Isc-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model. Clin Cancer Res 17(13):4474–4483PubMedCrossRef

27.

Chaudhry P, Singh M, Parent S, Asselin E (2012) Prostate Apoptosis Response-4 (Par-4): A Novel Substrate of Caspase-3 during Apoptosis Activation. Mol Cell Biol 32(4):826–839PubMedCrossRef

28.

Oberst MD, Beberman SJ, Zhao L, Yin JJ, Ward Y, Kelly K (2008) TDAG51 is an ERK signaling target that opposes ERK-mediated HME16C mammary epithelial cell transformation. BMC Cancer 8:189PubMedCrossRef

29.

Toyoshima Y, Karas M, Yakar S, Dupont J, Lee H, LeRoith D (2004) TDAG51 mediates the effects of insulin-like growth factor I (IGF-I) on cell survival. J Biol Chem 279:25898–25904PubMedCrossRef

30.

Oberg HH, Sipos B, Kalthoff H, Janssen O, Kabelitz D (2004) Regulation of T-cell death-associated gene 51 (TDAG51) expression in human T-cells. Cell Death Differ 11(6):674–684PubMed

31.

Johnson EO, Chang KH, de Pablo Y, Ghosh S, Mehta R, Badve S, Shah K (2011) PHLDA1 is a crucial negative regulator and effector of Aurora A kinase in breast cancer. J Cell Sci 124(Pt 16):2711–2722PubMedCrossRef

32.

Sakthianandeswaren A, Christie M, D’Andreti C, Tsui C, Jorissen RN, Li S, Fleming NI, Gibbs P, Lipton L, Malaterre J, Ramsay RG, Phesse TJ, Ernst M, Jeffery RE, Poulsom R, Leedham SJ, Segditsas S, Tomlinson IP, Bernhard OK, Simpson RJ, Walker F, Faux MC, Church N, Catimel B, Flanagan DJ, Vincan E, Sieber OM (2011) PHLDA1 Expression Marks the Putative Epithelial Stem Cells and Contributes to Intestinal Tumorigenesis. Cancer Res 71(10):3709–3719PubMedCrossRef

33.

Ohyama M, Terunuma A, Tock CL, Radonovich MF, Pise-Masison CA, Hopping SB, Brady JN, Udey MC, Vogel JC (2006) Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 116:249–260PubMedCrossRef

34.

Sellheyer K (2011) Stem cell markers can help identify adnexal tumor differentiation when evaluated in the context of morphology: methodology matters. J Cutan Pathol 38(6):460–474PubMedCrossRef

35.

Sellheyer K, Nelson P (2011) Follicular stem cell marker PHLDA1 (TDAG51) is superior to cytokeratin-20 in differentiating between trichoepithelioma and basal cell carcinoma in small biopsy specimens. J Cutan Pathol 38:542–550PubMedCrossRef

Title: Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas
Authors: Cláudia Malheiros Coutinho-Camillo
Silvia Vanessa Lourenço
Suely Nonogaki
José Guilherme Vartanian
Maria Aparecida Nagai
Luiz Paulo Kowalski
Fernando Augusto Soares
Publication date: 01-07-2013
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 1/2013
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-013-1438-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Expression of PAR-4 and PHLDA1 is prognostic for overall and disease-free survival in oral squamous cell carcinomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Platelet derived growth factor receptor-beta (PDGFRβ) expression is limited to activated stromal cells in the bone marrow and shows a strong correlation with the grade of myelofibrosis

Erratum to: Multidrug resistance protein 4 (MRP4) expression in prostate cancer is associated with androgen signaling and decreases with tumor progression

Renal angiomyolipoma, fat-poor variant—a clinicopathologic mimicker of malignancy

Expression of peroxiredoxins I and IV in multiple myeloma: association with immunoglobulin accumulation

Predicting dedifferentiation in liposarcoma: a proteomic approach

Pseudo-micropapillary structures associated with columnar cell lesions of the breast are an artifact due to traumatic epithelial detachment: a potential pitfall which can lead to overtreatment